Cargando…
Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
The current COVID-19 pandemic is associated with unprecedented morbidity and mortality. Early reports suggested an association between disease severity and hypertension but did not account for sources of confounding. However, the responsible virus — SARS-CoV-2 — gains entry to host cells via angiote...
Autores principales: | South, Andrew M., Tomlinson, Laurie, Edmonston, Daniel, Hiremath, Swapnil, Sparks, Matthew A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118703/ https://www.ncbi.nlm.nih.gov/pubmed/32246101 http://dx.doi.org/10.1038/s41581-020-0279-4 |
Ejemplares similares
-
Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System
por: Edmonston, Daniel L., et al.
Publicado: (2020) -
Renin–angiotensin system blockade in the COVID-19 pandemic
por: Cohen, Jordana B, et al.
Publicado: (2021) -
Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020) -
Renin-angiotensin system inhibitors in hospitalised patients with COVID-19
por: Williams, Bryan
Publicado: (2021) -
Renin–angiotensin system inhibition in COVID-19 patients: Friend or foe?
por: Karadağ, Bilgehan
Publicado: (2020)